The impact of the fourth edition of the WHO classification of lung tumours on histological classification of resected pulmonary NSCCs

Journal of Thoracic Oncology

Volumn 11, Issue 6, 2016, Pages 862-872

  Micke, Patrick ^a   Mattsson, Johanna Sofia Margareta ^a   Djureinovic, Dijana ^a   Nodin, Bjorn ^b   Jirstrom, Karin ^b,c   Tran, Lena ^c   Jonsson, Per ^d   Planck, Maria ^b,e   Botling, Johan ^a   Brunnstrom, Hans ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Region Skane ^*  (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Lung cancer; NSCC; p40; Pathology; TTF 1

Indexed keywords

CYTOKERATIN 5; MUCIN; NAPSIN A; PROTEIN; PROTEIN P40; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SARCOMATOID CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION; WORLD HEALTH ORGANIZATION CLASSIFICATION FOURTH EDITION; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLASSIFICATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMORS; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; SMALL CELL LUNG CARCINOMA; WORLD HEALTH ORGANIZATION;

EID: 84979729456     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.01.020     Document Type: Article

References (43)

1. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Phar-macother. 2009;43:490-501.
2. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6:64-70.
3. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lym-phoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. J Clin Oncol. 2014;32:3673-3679.
4. Kazandjian D, Khozin S, Blumenthal G, et al. Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: a report from the US Food and Drug Administration. JAMA Oncol. 2016;2:118-122.
5. Sandelin M, Berglund A, Sundström M, et al. Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome. Anticancer Res. 2015;35:3979-3985.
6. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015.
7. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
8. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocar-cinoma. J Thorac Oncol. 2011;6:244-285.
9. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.
10. Nonaka D. A study of DNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol. 2012;36:895-899.
11. Pelosi G, Rossi G, Cavazza A, et al. DNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013;21: 229-239.
12. Kadota K, Nitadori J, Rekhtman N, et al. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol. 2015;39:1170-1180.
13. Tran L, Mattsson JSM, Nodin B, et al. Various antibody clones of napsin A, thyroid transcription factor 1 and p40 and comparisons with cytokeratin 5 and p63 in histo-pathological diagnostics of non-small cell lung carcinoma [e-pub ahead of print]. Appl Immunohistochem Mol Morphol. http://dx.doi.org/10.1097/PAI.000000000000 0235, accessed May 11, 2016.
14. Rekhtman N, Ang DC, Sima CS, et al. Immunohisto-chemical algorithm for differentiation of lung adeno-carcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24:1348-1359.
15. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010;18: 142-149.
16. Brunnström H, Johansson L, Jirström K, et al. Immuno-histochemistry in differential diagnostics of primary lung cancer-an investigation within the Southern Swedish Lung Cancer Study. Am J Clin Pathol. 2013;140:37-46.
17. Manjer J, Carlsson S, Elmståhl S, et al. The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10:489-499.
18. Manjer J, Elmståhl S, Janzon L, et al. Invitation to a population-based cohort study: differences between subjects recruited using various strategies. Scand J Public Health. 2002;30:103-112.
19. Travis WD, Brambilla E, Nicholson AG, et al, WHO Panel. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243-1260.
20. Petersen I, Warth A. Lung cancer: developments, concepts, and specific aspects of the new WHO classification. J Cancer Res Clin Oncol. 2015;142:895-904.
21. Compérat E, Zhang F, Perrotin C, et al. Variable sensitivity and specificity of TTF-1 antibodies in lung meta-static adenocarcinoma of colorectal origin. Mod Pathol. 2005;18:1371-1376.
22. Surrey LF, Frank R, Zhang PJ, et al. TTF-1 and napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels. Am J Surg Pathol. 2014;38:224-227.
23. Ellery P, Archard N, Saetta A, et al. TTF-1 positive breast cancer: a cautionary tale. J Clin Pathol. 2015;68:665-666.
24. Choi SM, Furth EE, Zhang PJ. Unexpected TTF-1 positivity in a subset of gastric adenocarcinomas [e-pub ahead of print]. Appl Immunohistochem Mol Morphol. http://dx. doi.org/10.1097/PAI.0000000000000244, accessed May 11, 2016.
25. Wang LJ, Greaves WO, Sabo E, et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol. 2009;17:505-511.
26. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
27. Zhang P, Han YP, Huang L, et al. Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma. Oncol Lett. 2010;1:899-903.
28. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-661.
29. Tacha D, Yu C, Bremer R, et al. A 6-antibody panel for the classification of lung adenocarcinoma versus squa-mous cell carcinoma. Appl Immunohistochem Mol Mor-phol. 2012;20:201-207.
30. Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163-171.
31. Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. His-topathology. 2012;61:1017-1025.
32. Ye J, Hameed O, Findeis-Hosey JJ, et al. Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. Biotech Histochem. 2012;87:30-34.
33. Kim MJ, Shin HC, Shin KC, et al. Best immunohisto-chemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Ann Diagn Pathol. 2013;17:85-90.
34. Ao MH, Zhang H, Sakowski L, et al. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol. 2014;45:926-934.
35. Nagashio R, Ueda J, Ryuge S, et al. Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer. Sci Rep. 2015;5:8649.
36. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003;41:155-162.
37. Chang YL, Lee YC, Liao WY, et al. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer. 2004;44:149-157.
38. Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchio-loalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer. 2010;68:185-191.
39. Tatsumori T, Tsuta K, Masai K, et al. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Appl Immunohistochem Mol Morphol. 2014;22:377-382.
40. Ma Y, Fan M, Dai L, et al. Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. Thorac Cancer. 2015;6:288-295.
41. Koh J, Go H, Kim MY, et al. A comprehensive immuno-histochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. Histopathology. 2014;65:868-878.
42. Zhao W, Wang H, Peng Y, et al. DNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol. 2014;7:4247-4253.
43. Zachara-Szczakowski S, Verdun T, Churg A. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. Hum Pathol. 2015;46:776-782.